Dose Insider / Glossary / Titration

TitrationWhat it means and how each GLP-1 dose climbs

Updated November 20, 2026 · 3 min read · FDA and DailyMed labels of 8 medicines, 2025-2026

Titration means starting a medicine at a low dose and raising it in steps until the dose that will be kept, called the maintenance dose. Every GLP-1 medicine is titrated, and the labels give the same main reason: to reduce the risk of stomach and gut side effects such as nausea, vomiting and diarrhea.

week 21Zepbound 15 mg, week of the first top dose
Week of the first top doseAt the fastest pace each label allowsZepbound 15 mgweek 21Wegovy 2.4 mgweek 17Ozempic 2 mgweek 13Trulicity 4.5 mgweek 13Saxenda 3 mgweek 5Week of the first top doseAt the fastest pace each label allowsZepbound 15 mgweek 21Wegovy 2.4 mgweek 17Ozempic 2 mgweek 13Trulicity 4.5 mgweek 13Saxenda 3 mgweek 5

Every label allows a slower climb if side effects are hard to bear.

On this page

The starting doses are often too low to treat anything; the Rybelsus label says outright that its 3 mg start is not effective for blood sugar control.1,2,3

The ladder of each medicine

MedicineStartStepsTop dose
Ozempic0.25 mg weekly0.5, 1, 2 mg, every 4 weeks or more2 mg
Wegovy injection0.25 mg weekly0.5, 1, 1.7, 2.4 mg, every 4 weeks7.2 mg for some adults
Zepbound, Mounjaro2.5 mg weekly+2.5 mg every 4 weeks or more15 mg
Trulicity0.75 mg weekly1.5, 3, 4.5 mg, every 4 weeks or more4.5 mg
Saxenda0.6 mg daily+0.6 mg every week3 mg
Wegovy tablets1.5 mg daily4, 9, 25 mg, every 30 days25 mg
Rybelsus3 mg daily7 mg, then 14 mg if needed, after 30 days each14 mg
Foundayo0.8 mg daily2.5, 5.5, 9, 14.5, 17.2 mg, every 30 days or more17.2 mg

Section 2 of each label.1,2,3,4,5,6,7

At the fastest pace each label allows, the first top dose comes in week 21 for Zepbound or Mounjaro 15 mg and in week 17 for Wegovy 2.4 mg. Ozempic 2 mg and Trulicity 4.5 mg arrive in week 13, and Saxenda 3 mg in week 5. The Wegovy tablet reaches 25 mg on day 91.1,2,4,5,6 Our pages on the dosing schedules of Zepbound, Wegovy and Ozempic turn each ladder into dates.

The top step is not always the goal

Several labels let the climb stop below the highest dose. Zepbound for weight is kept at 5, 10 or 15 mg, chosen by response and tolerability. Wegovy for weight in adults is kept at 2.4 mg, the recommended dose, or 1.7 mg, with 7.2 mg only for adults who tolerated 2.4 mg for at least 4 weeks and need more. Ozempic stops at 0.5 mg if blood sugar is controlled, and Rybelsus at 7 mg.1,2,3,4 Saxenda is the exception: for adults 3 mg is the only treatment dose, and if it cannot be tolerated the label says to stop.6

Going slower

The labels give minimum gaps, not fixed dates. The Wegovy label says that if a dose is not tolerated during the climb, the next step can be delayed by 4 weeks, and the Saxenda label allows about one extra week.2,6 Whether to wait is the prescriber's call. The Zepbound label shows why the steps matter. In its weight trials, stomach and gut reactions were reported by 56% on each dose against 30% on placebo, and most nausea, vomiting and diarrhea occurred during the climb and decreased over time.4 Between 1.9% and 4.3% stopped Zepbound because of them, against 0.5% on placebo. Our page on the Zepbound dosing schedule lets you shift any step.

Starting again after a break

Titration can also happen twice. If 2 or more Wegovy doses in a row are missed, the label says to restart the climb at a lower dose. Foundayo restarts lower after 7 or more missed days, and Saxenda at 0.6 mg after more than 3 days.2,6,7 The reason is the same as at the start: a body that has lost its adjustment is more likely to react to a full dose.

Sources

  1. OZEMPIC (semaglutide) injection prescribing information, NDA 209637/S-039, revised May 2026. U.S. Food and Drug Administration; section 2.2. accessdata.fda.gov
  2. WEGOVY (semaglutide) prescribing information, NDA 215256/S-025, revised June 2026. U.S. Food and Drug Administration; section 2. accessdata.fda.gov
  3. RYBELSUS and OZEMPIC (semaglutide) tablets prescribing information, revised January 2026. Novo Nordisk; DailyMed, version published August 19, 2026; section 2.2. dailymed.nlm.nih.gov
  4. ZEPBOUND (tirzepatide) prescribing information, NDA 217806/S-041, revised August 2026, sections 2 and 6.1; and MOUNJARO (tirzepatide) prescribing information, NDA 215866/S-052, revised April 2026, section 2. U.S. Food and Drug Administration. accessdata.fda.gov
  5. TRULICITY (dulaglutide) injection prescribing information. Eli Lilly and Company; DailyMed, version published August 10, 2026; section 2. dailymed.nlm.nih.gov
  6. SAXENDA (liraglutide) injection prescribing information. Novo Nordisk; DailyMed, version published June 15, 2026; section 2. dailymed.nlm.nih.gov
  7. FOUNDAYO (orforglipron) tablets prescribing information. Eli Lilly and Company; DailyMed, version published August 13, 2026; section 2. dailymed.nlm.nih.gov

Related analyses

Log each step of your climb and see your own dates on a calendar.

Open Dose Insider